High-titer IVIG 10 % (human)-slra reduces infections and hospitalizations over 6 to 12 months: A retrospective quality improvement study.

Patients with primary or secondary immunodeficiencies are at an increased risk for recurrent respiratory infections despite standard intravenous immunoglobulin (IVIG) therapy. This retrospective quality improvement review evaluated the clinical impact of a high-titer IVIG product enriched with pathogen-specific antibodies in 14 patients after failing conventional IVIG. The primary outcomes were changes in infection frequency and hospitalization rates during the 6 months before and after treatment initiation, and from 6 months post-treatment to the present. Ten patients (71%) showed clinical improvement, with infections decreasing from 36 to 8 and hospitalizations from 14 to 5 in the first 6 months post-treatment; benefits were more pronounced when excluding one clinical outlier. Two patients discontinued therapy due to mild adverse effects or lack of efficacy. High-titer IVIG was associated with meaningful reductions in infection burden and hospitalizations, supporting its consideration for high-risk patients unresponsive to standard IVIG.